214 related articles for article (PubMed ID: 32424651)
1. Inpatient Initiation of Oral Treprostinil in an Academic Medical System.
Hohlfelder B; Tonelli AR; Heresi GA; Bair N; Rahaghi FF; Bauer SR
Cardiovasc Drugs Ther; 2020 Aug; 34(4):547-553. PubMed ID: 32424651
[TBL] [Abstract][Full Text] [Related]
2. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
4. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
5. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
Coons JC; Miller T
Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
[TBL] [Abstract][Full Text] [Related]
6. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Kimmig LM; Liao C; Bag R
Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
[TBL] [Abstract][Full Text] [Related]
7. Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.
Xu N; Huang ST; Sun KP; Wang ZC; Cao H; Chen Q
BMC Cardiovasc Disord; 2020 Nov; 20(1):472. PubMed ID: 33143649
[TBL] [Abstract][Full Text] [Related]
8. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
9. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension.
Hopper RK; Ivy DD; Yung D; Mullen MP; Hanna BD; Kirkpatrick E; Hirsch R; Austin ED; Fineman J; Solum D; Deng CQ; Feinstein JA
J Cardiovasc Pharmacol; 2020 Jul; 76(1):94-100. PubMed ID: 32398473
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
[No Abstract] [Full Text] [Related]
12. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
13. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
14. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
Sarangarm P; Elwood K
Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
16. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension.
Olsson KM; Richter MJ; Kamp JC; Gall H; Heine A; Ghofrani HA; Fuge J; Ewert R; Hoeper MM
J Heart Lung Transplant; 2019 Jul; 38(7):748-756. PubMed ID: 31128966
[TBL] [Abstract][Full Text] [Related]
17. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
18. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
19. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
El-Kersh K; Ruf KM; Smith JS
Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
[TBL] [Abstract][Full Text] [Related]
20. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
Ataya A; Somoracki A; Cope J; Alnuaimat H
Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
